A promise on the stage, a trial in the courtroom

A STUDIO CEO takes the stage before the owners of the nation's cinemas, looks them in the eye and promises that his company will make at least 30 films a year for the big screen. It sounds like a covenant. It is better understood as a negotiating tactic.

Last April David Ellison, Paramount Skydance's chairman and chief executive, told the CinemaCon audience in Las Vegas that once his $111 billion acquisition of Warner Bros. Discovery closes, the combined entity will release a minimum of 30 theatrical films annually, each with a 45-day exclusive run in cinemas before appearing on streaming. He was not merely repeating a slogan. He was trying to grease the wheels of a deal that had already been rejected eight times by the Warner Bros. Discovery board and was facing mounting resistance from Hollywood creatives, state attorneys general and the very exhibitors he was addressing.

The promise was, and remains, unenforceable. That is the key word.

The arithmetic of a pledge

Mr Ellison's arithmetic is deceptively simple. Paramount has already increased its own slate from eight films in 2025 to 15 this year. Warner Bros. was planning a similar number for 2026. Add the two together and you get 30. The logic is tidy. The history of studio mergers is less so.

When Disney acquired 21st Century Fox in 2019, the combined studio released fewer theatrical films, not more. Redundancies were eliminated; slates were trimmed. Disney averaged 12-13 releases annually afterwards, below Fox and Searchlight's pre-merger run rate. The standard pattern of consolidation is contraction. Mr Ellison is asking theater owners to believe his will be the exception.

He has a reason to ask. His personal financial exposure is enormous. Bloomberg reports the Ellison family faces up to $9.8 billion in potential losses if the deal collapses: a $7 billion regulatory termination fee and the $2.8 billion he paid Netflix to abandon its competing bid. On top of that, Paramount faces a ticking fee of approximately $7 million a day to Warner Bros. Discovery for every day the transaction remains unclosed past September 30th. The company agreed on July 24th not to close until at least June 1, 2027, or five days after a court ruling on the merits, whichever comes first.

The incentive is clear. A public, emphatic commitment to theatrical output is the cheapest possible way to win over exhibitors, deflect the narrative that this deal will kill cinema and present regulators with the image of a cinephile rather than a consolidator. Mr Ellison is not making promises for free.

Who believes him, and who does not

The theatrical industry is split along predictable lines. AMC, the largest cinema chain, has Mr Ellison's back. Adam Aron, AMC's chief executive, published an op-ed in Variety this July endorsing the merger. He dismissed the antitrust lawsuit brought by a coalition of 12 state attorneys general and argued that the real threat to exhibition is not studio concentration but a thinning film pipeline. A bigger, better-capitalized studio, he contends, can compete with technology giants for content volume and marketing muscle.

His reasoning is not unattractive. AMC reported a record quarter in the second half of 2026, with revenues of $1.6bn, up 14% year on year. Mr Aron's problem is not that his own theaters are empty; it is that his competitors might be. A reliable flow of blockbusters from a merged Paramount-Warner entity helps AMC more than it helps the regional chains that cannot depend on the same density of hit titles.

Cinema United, the trade group that represents the wider exhibition industry, tells a different story. Michael O'Leary, its chief executive, has described Mr Ellison's pledges as "high-level and unenforceable." He notes that no studio in the past 25 years has released 30 wide films in a single year, and that the combined entity will carry roughly $79 billion in debt — a burden that historically leads to cost cuts, not creative expansion. Cinema United submitted a list of concerns to Paramount on July 1st and, by late July, said it had not received a response.

A Paramount spokesperson disputed this, saying the company had offered "enforceable commitments" but that Cinema United's lawyers subsequently introduced "new demands unrelated to the merger." The dispute over what is, and is not, binding is itself telling. It suggests that the "written pledge" Mr Aron invoked in his op-ed has not been incorporated into any legal document that exhibitors can enforce.

The legal brake

On July 20th, a federal judge granted a temporary restraining order that put the merger on hold. The order was extended through mid-August before Paramount and the plaintiffs agreed to skip the preliminary-injunction fight and proceed straight to a trial scheduled for March 2nd next year in the Northern District of California. The merger cannot close until June 1st, 2027, at the earliest.

The suit is led by California's attorney general, Rob Bonta, on behalf of 12 states. It argues that the deal violates the Clayton Act by substantially lessening competition in theatrical film distribution, blockbuster licensing and basic-cable television. The Writers Guild of America filed a separate suit alleging the merger would limit competition for writers' services. The federal Justice Department, by contrast, cleared the deal in June.

All this means that Mr Ellison's 30-film pledge is, for now, a promise made in the shadow of a lawsuit that could erase the very company it was designed to protect. If the merger falls apart, the theatrical commitments vanish with it. Even if it survives, the pledge is personal to its chief executive. Studio heads have come and gone; contracts endure. Exhibitors who take Mr Ellison at his word are betting that his incentives will not change once he is in control.

The deeper problem

To be sure, the theatrical ecosystem has genuine problems. Post-pandemic box-office revenue in the United States and Canada has not surpassed $10bn, down from pre-pandemic peaks above $11bn. Screens sit idle; re-releases and sports screenings fill gaps that once belonged to wide-release features. A guarantee of 30 new films a year from the combined studio — even if only half of them are tentpoles — would be a lifeline.

Yet the structural danger is not that Paramount will fail to deliver 30 films. It is that the merger will succeed and the industry will be left with four major studios instead of five. Fewer distributors means fewer alternatives for theaters to push back on revenue splits, screen placement and scheduling. That is precisely the dynamic Cinema United is trying to prevent, and it is the argument the states' attorneys general are putting before a judge. Monopoly power does not usually announce itself with a manifesto. It arrives quietly, after the vote, after the closing, after the pledges have been fulfilled once or twice and then quietly reinterpreted.

What should happen next

The better answer is not to rely on a chief executive's goodwill. Exhibitors should insist that theatrical-window commitments be baked into the merger's regulatory conditions, not left as statements of intent. Regulators should treat content volume and window length as part of the competitive analysis, not as afterthoughts. The trial in March 2027 will determine whether the deal proceeds; it should also set terms if it does.

Mr Ellison is not a cartoon villain. He has genuine enthusiasm for cinema and has invested his own capital to keep Paramount independent after its decline under ViacomCBS. His slate decisions may well deliver popular films. But sincerity is not a substitute for institutional guardrails. Promises made on a stage are easy to break once the spotlight moves elsewhere. The exhibitors would do well to remember that.

The first question in any merger is not what the acquirer says. It is what the market looks like afterwards. Fewer studios, more debt and unenforceable pledges do not add up to a healthier theatrical ecosystem. They add up to less competition, dressed in a better slogan.